Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ALB | P02768 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | POLA1 | P09884 | 1/20 | 0.59 |
| ▸ | POLD1 | P28340 | 1/20 | 0.59 |
| ▸ | BCHE | P06276 | 10/20 | 0.51 |
| ▸ | TK1 | P04183 | 3/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.48 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Stavudine Triphosphate SCHEMBL26731736 | 1.00 | POLB (0.60) | POLBALDH1A1LMNAALBADRA1A | |
| SCHEMBL26309128 | 0.98 | POLB (0.62) | POLBALDH1A1LMNAALBADRA1A | |
| SCHEMBL26731712 | 0.98 | POLB (0.62) | POLBALDH1A1LMNAALBADRA1A | |
| SCHEMBL26731814 | 0.89 | ALDH1A1 (0.67) | POLBALDH1A1LMNAALBADRA1A | |
| SCHEMBL124991 | 0.89 | ALDH1A1 (0.67) | POLBALDH1A1LMNAALBADRA1A | |
| SCHEMBL26309146 | 0.85 | POLB (0.56) | POLBALDH1A1LMNAALBADRA1A | |
| SCHEMBL9856521 | 0.81 | POLG (0.50) | POLBPOLA1POLD1P2RY2P2RY6 | |
| SCHEMBL26309162 | 0.81 | POLB (0.53) | POLBALDH1A1LMNAALBADRA1A | |
| SCHEMBL18855348 | 0.80 | POLB (0.68) | POLBPOLA1POLD1BCHETK1 | |
| SCHEMBL3031874 | 0.80 | POLB (0.68) | POLBPOLA1POLD1BCHETK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024238925-A2 | COMPOSITIONS AND METHODS FOR INDUCING VIRAL MIMICRY IN CANCER CELLS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-11-21 | — | — | WO | claimed |
| EP-0517986-B1 | Transformed erythrocytes, process for preparing the same, and their use in pharmaceutical compositions | EUROP COMMUNITIES (LU) | 1997-09-10 | — | — | EP | claimed |
| US-5576177-A | DETERMINING EFFICACY OF HUMAN T-CELL LEUKEMIA/LYMPHOMA INFECTION TREATMENT | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 1996-11-19 | — | — | US | claimed |
| CN-120051271-A | Methods for treating infectious diseases | 欣扬生医股份有限公司 | 2025-05-27 | — | — | CN | disclosed |
| EP-4522128-A1 | METHOD FOR TREATING INFECTIOUS DISEASE | Suntec Medical, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250073163-A1 | METHOD FOR TREATING INFECTIOUS DISEASE | SUNTEC MEDICAL INC (US) | 2025-03-06 | — | — | US | disclosed |
| WO-2024238925-A2 | COMPOSITIONS AND METHODS FOR INDUCING VIRAL MIMICRY IN CANCER CELLS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-11-21 | — | — | WO | disclosed |
| WO-2023220086-A1 | METHOD FOR TREATING INFECTIOUS DISEASE | SUNTEC MEDICAL, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023178127-A1 | METHODS OF TREATING MEDICAL CONDITIONS USING STAMPIDINE OR A RELATED COMPOUND | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-7875422-B2 | in an enveloped virus-infected mammalian individual by testing on an enzyme packed into an enveloped virus, such as HIV, recovered from a biological sample, such as blood or plasma | CAVIDI AB (SE) | 2011-01-25 | — | — | US | disclosed |
| US-20100021888-A1 | Screening for disease susceptibility by genotyping the CCR5 and CCR2 genes | BOARD OF REGENTS | 2010-01-28 | — | — | US | disclosed |
| US-7393634-B1 | Screening for disease susceptibility by genotyping the CCR5 and CCR2 genes | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 2008-07-01 | — | — | US | disclosed |
| EP-1395676-B1 | VIRAL DRUG SUSCEPTIBILITY TESTING | CAVIDI TECH AB (SE) | 2006-01-18 | — | — | EP | disclosed |
| US-20040170958-A1 | Viral drug susceptibility testing | EUROPEAN INVESTMENT BANK (LU) | 2004-09-02 | — | — | US | disclosed |
| WO-2001027330-A2 | SCREENING FOR DISEASE SUSCEPTIBILITY BY GENOTYPING THE CCR5 AND CCR2 GENES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2001-04-19 | — | — | WO | disclosed |
| WO-2001012831-A2 | ANTI-BACTERIAL AND ANTI-VIRAL COMPOSITIONS AND METHODS | UT-BATTELLE, LLC (US) | 2001-02-22 | — | — | WO | disclosed |
| US-5753221-A | CONTAINING TRIPHOSPHORYLATED NUCLEOSIDE ANALOG WHICH INHIBITS REVERSE TRANSCRIPTASE; VIRICIDES | COMMUNAUTE ECONOMIQUE EUROPEENE (LU) | 1998-05-19 | — | — | US | disclosed |
| EP-0517986-B1 | Transformed erythrocytes, process for preparing the same, and their use in pharmaceutical compositions | EUROP COMMUNITIES (LU) | 1997-09-10 | — | — | EP | disclosed |
| EP-0517986-A1 | Transformed erythrocytes, process for preparing the same, and their use in pharmaceutical compositions | COMMUNAUTE ECONOMIQUE EUROPEENNE (CEE) (LU) | 1992-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250073163-A1 | METHOD FOR TREATING INFECTIOUS DISEASE | CD14, PML, SARS1 | POLB 369/4885ALDH1A1 4505/4885LMNA 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.